Evidence map›Paper›PMID 39457104›Full record

ArticleInternational journal of molecular sciences2024

Precision Oncology in Older Cancer Patients: A Single-Center Experience.

Meret Petitat-Berli, Marie Knufinke, Michèle Voegeli, Martina Sonderegger, Bettina Seifert, Elena Diana Chiru, Pirmin Haeuptle, Lisanne Van't Walderveen, Robert Rosenberg, Emanuel Burri and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Meret Petitat-BerliCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Marie KnufinkeCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Michèle VoegeliCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Martina SondereggerCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Bettina SeifertCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Elena Diana ChiruCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Pirmin HaeuptleCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Lisanne Van't WalderveenCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Robert RosenbergColorectal Cancer Center, Cantonal Hospital Baselland, 4410 Liestal, Switzerland.
Emanuel BurriColorectal Cancer Center, Cantonal Hospital Baselland, 4410 Liestal, Switzerland.ORCID 0009-0009-3506-8447
Svetozar SuboticClinic of Urology, Cantonal Hospital Baselland, 4410 Liestal, Switzerland.
Fabienne Dominique SchwabGynecologic Cancer Center, University Hospital of Basel, University of Basel, 4031 Basel, Switzerland.
Vérène Dougoud-ChauvinClinic of Oncology, HFR Fribourg Hospital, 1708 Fribourg, Switzerland.
Heinz UngerCenter of Geriatric Medicine and Rehabilitation, Cantonal Hospital Baselland, 4101 Bruderholz, Switzerland.
Kirsten MertzInstitute of Pathology, Cantonal Hospital Baselland, 4410 Liestal, Switzerland.ORCID 0000-0002-3074-6925
Loay TahanCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.
Marcus VetterCenter of Oncology and Hematology, Medical University Clinic Baselland, 4410 Liestal, Switzerland.ORCID 0009-0004-1003-1078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last two decades, next-generation sequencing (NGS) has facilitated enormous progress in cancer medicine, in both diagnosis and treatment. However, the usefulness of NGS in older cancer patients is unclear. To determine the role of NGS in older cancer patients, we retrospectively assessed demographic, clinicopathologic, and disease-specific data from 100 randomly selected cancer patients (any subtype/stage) who underwent NGS testing in 2020 at our institution and compared the treatment outcomes (progression-free survival [PFS] and overall survival [OS]) in the younger and older patient cohorts (A [n = 34] and B [n = 66]: age < 70 and ≥70 years, respectively). Overall, 27% had targetable mutations, and 8% received NGS-determined targeted therapy (45% and 19% of patients with a targetable mutation in cohorts A and B, respectively;

Indexed as

High-Throughput Nucleotide SequencingMutationNeoplasmsPrecision MedicineAdultAgedAged, 80 and overAge FactorsFemaleHumansMaleMiddle AgedMolecular Targeted TherapyPilot ProjectsRetrospective Studiesmetastatic cancernext generation sequencingolder cancer patientsprecision oncology

Identifiers

PMID39457104
PMCPMC11508622

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.